were used as denominators in the calculation of incremental CE ratios (ICER) are decreased frequencies of mild hypoxia, severe hypoxia and pneumonia. RESULTS: Frequencies of residual NMB were estimated as 51.2% 44.6% and 0.4% in SR, neostigmine and Bridion groups, respectively. Hypoxia rate was calculated as 27.4% and 11.4% in patients with and without residual NMB. Frequencies of pneumonia were 17.2% and 5.9% in patients with and without residual NMB. Percentage of patients without any complication was found to be 88.0% in Bridion group, while it was 73.8% and 75.7% in SR and neostigmine groups. The costs of complications were 126. 45 c and 114. 56 c in SR and neostigmine groups, while it was only 34. 93 c in Bridion® group. When medication cost was added, the total cost rose to 114. 62 c in Bridion® group, which was still lower than the total costs of SR and neostigmine groups. The rate of severe hypoxia was estimated as 7.9% in Bridion® group, while it was 13.5% and 12.7% in SR and neostigmine groups, respectively. Pneumonia was seen in 1.2% of the patients in Bridion® group, while the frequencies of pneumonia were 9.4% and 8.3% in SR and neostigmine groups. CONCLUSIONS: Bridion® was found to be dominant to both SR and neostigmine groups, in terms of decrease in frequencies of hypoxia and pulmonary complications. OBJECTIVES: To conduct pharmacoeconomic evaluation of Levodopa/Carbidopa/ Entacapone (LCE) compared to standard therapy in Parkinson disease treatment. Standard therapy was presented by Levodopa and Carbidopa. METHODS: The costeffectiveness study was carried conducted. Effectiveness was measured in DALYs. Time horizont for cost-effectiveness analysis was 2 years. a 3% discount rate was used. 1 EUR = 40 RUB. RESULTS: LCE provided benefi ts in effectiveness compared to standard therapy. LCE reduced days incapacity index twice from 44 to 21 days. Two year pilot study showed that LCE provided 0,83 DALY, than standard therapy presented 0,5 DALY. Also administration of LCE reduced daily Levodopa dose on 68 mg. Total annual costs for LCE therapy were 158 938 (3 974 EUR) RUB. Standard therapy total costs varied from 129 113 RUB (3 228 EUR) to 145 422 RUB (3 636 EUR) yearly according to disease progression grade. Indirect costs, including GDP losses due to temporary disability and payments for temporary disability, were 14 372 RUB (359 EUR) for LCE and 30 113 RUB (753 EUR) for standard therapy. The costeffectiveness ratio for LCE was 191 492 RUB (4 787 EUR) per DALY, than for standard therapy it was 258 326 RUB (6 458 EUR) per DALY. CONCLUSIONS: LCE demonstrates lower cost-effectiveness ratio (191 492 RUB) compared to standard Parkinson disease therapy (258 326 RUB), therefore LCE has an advantage over standard therapy in terms of pharmacoeconomic evaluation. OBJECTIVES: Adherence to cost-effectiveness analytic guidelines requires careful assessment of clinical trial results to ensure the most appropriate cohort data selection. This study examines the impact of cohort selection on the results of the Goldberg, et al. 2009 cost-effectiveness study of disease-modifying therapies (DMTs) in multiple sclerosis (MS). METHODS: Using intent-to-treat (ITT) two-year data from pivotal trials, Goldberg compared cost per relapse avoided of fi rst-line DMTs. However, there are important differences in the ITT cohorts among the trials. Due to lower than expected subject drop-out rates, the interferon beta-1a IM (INF-b-1a-IM) trial was able to meet its primary endpoint with a reduced sample size and a decision was made to terminate the trial early. This resulted in almost half of the 301 ITT (or "allpatient") cohort being on study drug for less than two years. a second, "two-year" 172 patient cohort consisted of patients who had completed two years on drug therapy. Goldberg used the INF-b-1a-IM "all-patient" cohort in his cost study. To test the impact of this cohort selection, we recreated Goldberg's model using the "allpatient" relapse rate (0.67 for INF-b-1a-IM vs. 0.82 for placebo) and then substituted the "two-year" cohort data (relapse rate of 0.61 for INF-b-1a-IM vs. 0.90 for placebo) and compared results. RESULTS: This study's cost per relapse avoided was 45% lower for INF-b-1a-IM while the results for the other DMTs were comparable to those reported by Goldberg. Ranked from most to least cost-effective, the model results were $77,980 for INF-b-1a-IM, $80,121 for interferon beta-1a SC, $86,572 for interferon beta-1b, and $87,767 for glatiramer. CONCLUSIONS: Our analysis demonstrates the importance of cohort selection in cost-effectiveness analyses in MS. By selecting comparable cohort data from patients who had completed at least two years on study drug, we found that INF-b-1a-IM had the lowest cost per relapse avoided of all fi rstline DMTs.
PND25 ECONOMIC EVALUATION OF NATALIZUMAB IN THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN 4 EUROPEAN COUNTRIES
Brennig C, Walter E, Schöllbauer V Institute for Pharmaeconomic Research, Vienna, Austria OBJECTIVES: Multiple sclerosis (MS) is an infl ammatory, neurodegenerative condition of central nervous system with prevalence of 1 Million worldwide (age at fi rst manifestation 20-40 years). MS may lead to permanent disability and early retirement even in young adults. The purpose of this analysis was to provide an economic assessment of relapsing-remitting MS-treatment with Natalizumab versus Interferons and Copolymer in 4 European countries (Austria, Czech Republic, Slovakia, Slovenia) . METHODS: The analysis was performed using a Markov model. The model allows a treatment switch due to relapse. Effi cacy assessment was based on the outcome measure "relapse-free patients". Costs were captured for the year 2010. Resource use was determined from results of a survey conducted by the Austrian MS Society and accurately refl ects the therapeutic approach. Resource use of Czech Republic, Slovakia and Slovenia was determined via country-specifi c research. Where country specifi c data could not be captured, Austrian data was adjusted via Purchasing Power Parities (PPP). The study time horizon was 2 years. The analysis was performed from the perspective of the health care system of the 4 European countries. RESULTS: In Czech Republic the average cost of the therapy algorithm Natalizumab amount to c33,835 per patient within the time horizon of 2 years versus c22,896 (Interferon) and c21,256 (Copolymer). a patient successfully treated with Natalizumab accounts for c56,525 compared to c70,190 (Interferon) and for c87,555 (Copolymer). In Slovakia a relapsefree patient values c60,357 (Natalizumab) versus c58,043 (Interferon) and c19,921 (Copolymer). a relapse-free patient in Slovenia values c59,108 (Natalizumab) versus c66,202 (Interferon) and c84,207 (Copolymer). In Austria a relapse-free patient values c58,423 (Natalizumab) versus c71,906 (Interferon) and c89,591 (Copolymer). CON-CLUSIONS: In Czech Republic, Slovenia, and Austria, treatment of MS with Natalizumab is more cost-effective than Interferon resp. Copolymer 1 therapy. Switching to effective and more expensive alternatives does not account for higher health care costs.
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MEDICO-ECONOMIC EVALUATION OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PATIENTS WITH REFRACTORY EPILEPSY IN SCOTLAND AND SPAIN
Benhaddi H 1 , Gunn A 1 , Ferro B 2 1 UCB Pharma S.A., Brussels, Belgium; 2 UCB Pharma S.A., Madrid, Spain OBJECTIVES: To calculate and compare the incremental cost-utility ratios for standard antiepileptic drug (AED) therapy with and without adjunctive lacosamide in patients with uncontrolled partial-onset seizures. METHODS: The model simulated the treatment pathway of a hypothetical cohort of 1000 patients over 2 years from the perspectives of the National Health Service (NHS) in Scotland and the Spanish Healthcare System (SNS) in 2008. a decision tree was split into four phases of six months each during which patients can become seizure free, experience a seizure reduction (responder defi ned as ≥50% reduction in seizures), or withdraw due to non-response. The standard therapy arm included carbamazepine, lamotrigine, levetiracetam, topiramate, and valproate. The likelihood of being in a particular health state has been estimated from clinical data. The cost of general practitioner visits, outpatient visits, hospitalizations and emergency department visits were included. Costs and utility values attached to various health states were taken from the published literature. RESULTS: Lacosamide adjunctive therapy was associated with 6730 avoided seizures and a gain of 38 quality adjusted life-years (QALYs), compared to the standard therapy arm within the two-year timeframe. Treatment with lacosamide was associated with a cost of £113 and c107 per seizure avoided, and £20,017 and c22,771 per QALY gained versus standard therapy in Scotland and Spain, respectively. Results calculated for 6-, 12-and 18-month follow-up showed respective incremental cost-utility ratios of £23,479, £21,422 and £20,998 in Scotland, and c23,771, c20,703 and c21,778 in Spain. Using a willingness-to-pay threshold of £30,000 per QALY, 80% of the simulations in Scotland and 74.2% in Spain fell below this value after 2 years of treatment. CONCLUSIONS: Lacosamide was shown to be a cost-effective adjunctive treatment in patients with uncontrolled partial-onset epilepsy in Scotland and Spain.
PND27 COST UTILITY ANALYSIS OF ORPHAN DRUGS: CASE STUDY OF DUODENAL LEVODOPA INFUSION VERSUS STANDARD TREATMENT IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE IN SWEDEN
Willis M 1 , Gradl B 2 1 IHE, Lund, Sweden; 2 Abbott Products Operations AG, Allschwil, Switzerland BACKGROUND: Advanced Parkinson's disease (APD) severely impacts the quality of life (QoL) for both patients and their caregiver and is associated with high health care and societal costs. The treatment options for those patients are limited. Duodenal levodopa infusion (DLI), an orphan drug, has shown to restore symptom control and to improve QoL substantially for both patients and their carers. OBJECTIVES: To evaluate the cost-utility of DLI versus standard treatment (including oral treatment and subcutaneous dopamine agonists) in patients with advanced PD in Sweden. METHODS: A stochastic Markov-based simulation model was developed. Health was described by 12 health states refl ecting 4 categories of "OFF" time and 3 severity stages as measured by the Hoehn & Yahr scale. The clinical effect for both treatment arms was derived from published clinical trials; costs and QoL utilities were taken from an interim analysis of the ongoing DAPHNE study. The base case simulated 5 years with costs/effects discounted by 3%. The societal perspective was adopted. RESULTS: The model estimated an improvement from 0.68 to 1.30 QALYs and a cost increase from 1,410,643 (c147,108) to SEK 1,674,295 (c174,603) for DLI versus standard treatment, leading to an incremental cost-effectiveness ratio (ICER) of around SEK 420,000 (c43,800) per QALY gained. The ICER for nearly 90% of the cohorts fell below SEK 655,000 (c68,306), the willingness-to-pay threshold often cited 13th Euro Abstracts A393 for Sweden [1] . Sensitivity analysis was associated with ICERs ranging up to SEK 900,000 (c93,856) per QALY gained. CONCLUSIONS: Due to the data limitations, HE modeling in the orphan drug setting is challenging. Analysis could be performed as requested by Sweden's Dental and Pharmaceutical Benefi ts Agency (TLV), however, providing evidence that health benefi ts can provide good value for money even for an orphan population. DLI received a positive reimbursement recommendation by the TLV.
[1] Persson U, Hjelmgren J (2003).
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COST-UTILITY ANALYSIS OF ROTIGOTINE TRANSDERMAL PATCH IN EARLY-STAGE PARKINSON'S DISEASE IN SCOTLAND
Benhaddi H, Gunn A UCB Pharma S.A., Brussels, Belgium OBJECTIVES: To evaluate the cost-effectiveness of rotigotine transdermal patch as monotherapy in early-stage Parkinson's disease (PD) compared to ropinirole and other dopamine agonists (DA) from the NHS perspective in Scotland. METHODS: a decision-analytic model was developed, based on treatment of an early-stage PD patient (Hoehn and Yahr-stage 2); treatment arms were rotigotine, ropinirole, and a DA practice comparator including ropinirole, cabergoline and pramipexole. 5-year and 10-year time horizons were considered for patients who remained on monotherapy only. The economic evaluation is a cost-utility analysis with health outcomes expressed in Quality Adjusted Life-years (QALY) gained in 2006. Costs relating to drug acquisition, PD severity, falls, occurrence of motor complications and other complications/ adverse events/co-morbidities were considered in the model. Effi cacy and safety data were estimated with a meta-analysis. Quality of life was measured using EQ-5D. Data on medical resource use was obtained via expert interviews and literature review. Costs and effects were discounted at the rate of 3.5%. RESULTS: After 5 years, treatment with rotigotine transdermal patch resulted in an estimated 2.30 QALYs, slightly higher than with ropinirole (2.26) and the DA practice comparator (2.27). 10-year outcomes were 3.22, 3.17 and 3.17 QALYs for rotigotine, ropinirole and DA practice comparator, respectively. Total costs for rotigotine, ropinirole and DA practice comparator were £34,748, £37,694 and £36,459 respectively after 5 years and £79,477, £84,120 and £81,631, respectively after 10 years. With a willingness-to-pay of £20,000 per QALY gained, there is a 90% probability that rotigotine is cost-effective relative to ropinirole, and a 85% probability of cost-effectiveness relative to the DA practice comparator for both 5-year and 10-year time horizons. CONCLUSIONS: Based on the model, rotigotine may be considered a dominant strategy over ropinirole and DA practice comparator in the treatment of early-stage PD at 5-year and 10-year time horizons.
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COST-UTILITY ANALYSIS OF RIZATRIPTAN VERSUS (GENERIC) SUMATRIPTAN IN SWEDEN
Lundberg J 1 , Golden WM 2 , Insinga RP 3 1 MSD Sweden, Sollentuna, Sweden; 2 Merck & Co., Inc., Whitehouse Station, NJ, USA; 3 Merck & Co., Inc., Upper Gwynedd, PA, USA OBJECTIVES: In 2005 the Swedish pharmaceutical benefi ts board published a review concluding that rizatriptan 10 mg was one of the most cost-effective triptans for treating migraine, although effi cacy differences among the triptan class were generally small. However, since the review, the price of sumatriptan has declined due to generic product entry. In this study, we sought to investigate the cost-effectiveness of rizatriptan versus generic sumatriptan. METHODS: A published Canadian decision-analytic model (Thompson et al., Pharmacoeconomics 2005) was adapted to estimate treatment costs and effects of rizatriptan 10 mg versus (generic) sumatriptan in a single migraine attack over a 24-hour time-frame in Sweden. Values modifi ed from the published model were the substitution of Swedish health care and productivity costs, and updated data on 2-hour and 2-24 hour pain freedom (including results from more recent head-to-head trials of the comparators). As both sumatriptan 50 mg and 100 mg are marketed in Sweden, and have comparable effi cacy profi les, averaged data for the two doses were used as a comparator to rizatriptan 10 mg. RESULTS: From a societal perspective, including both health care and productivity costs, the comparison of rizatriptan 10 mg versus (generic) sumatriptan resulted in cost-savings of ~ 5 SEK, and greater QALYs for rizatriptan 10 mg. Inclusion of health care costs only, yielded a cost-effectiveness ratio for rizatriptan vs. sumatriptan of 343,929 SEK/ QALY. CONCLUSIONS: Given the data and assumptions used, in a single attack model, rizatriptan 10 mg was found to have a cost-effectiveness ratio compared to (generic) sumatriptan within the range typically regarded as cost-effective in Sweden. These fi ndings suggest that there is reason to explore the cost-effectiveness of pharmaceutical and other medical interventions with large differences in acquisition cost even though effi cacy differences may appear to be small.
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COST-UTILITY ANALYSIS OF LACOSAMIDE ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN EPILEPTIC PATIENTS IN BELGIUM
Simoens S 1 , Dedeken P 2 , De Naeyer L 2 , Benhaddi H 2 1 K.U. Leuven, Leuven, Belgium; 2 UCB Pharma S.A., Brussels, Belgium OBJECTIVES: This study aims at evaluating the incremental cost-effectiveness ratio (ICER) for lacosamide compared with standard therapy alone from the perspective of the Belgian health care payer in 2010. METHODS: A decision tree simulating the treatment pathway of a hypothetical cohort of 1,000 patients over two years was split into four phases of six months each during which patients can become seizure free, experience a seizure reduction (defi ned as ≥50% reduction in seizures), or withdraw due to non-response. The antiepileptic drugs (AEDs) included in the standard therapy arm were extracted from the pivotal trials and included carbamazepine, lamotrigine, levetiracetam, topiramate and valproate. Health state probabilities, seizure frequency and utility values were taken from lacosamide trials or from the literature. Costs of general practitioner visits, outpatient visits, hospitalizations and emergency department visits were included. Resource use was estimated by a Belgian panel of eight neurologists. Costs were discounted at a rate of 3% and consequences at a rate of 1.5%. RESULTS: Over a 24-month period, standard AED therapy plus lacosamide led to a reduction of 7 seizures, an increase of 0.038 quality-adjusted life-years, and a cost decrease of c3619 per patient as compared with standard therapy alone. Results were also calculated for a 6-, 12-and 18-month follow-up. Lacosamide plus AED therapy dominated versus standard therapy alone. Using a willingness to pay of c30,000 per quality-adjusted life-year, the net monetary benefi t of standard antiepileptic drug therapy plus lacosamide amounted to c4,754. The probability of standard AED therapy plus lacosamide being cost-effective was 97.3% at 6 months, 99.8% at 12 months, 99.9% at 18 months, and 100% at 24 months. CONCLUSIONS: In epileptic patients who are diffi cult to treat with other AEDs, standard AED therapy plus lacosamide appears to be a cost-effective alternative.
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IMPACT OF AN ADHERENCE PROGRAM, RUN AS A TELEPHONE INTERVENTION ON COMPLIANCE WITH SUBCUTANEOUS INTERFERON Â-1A FOR MULTIPLE SCLEROSIS PATIENTS USING A MAIL-ORDER PHARMACY
Papademetriou E 1 , Levin R 1 , Tuennermann M 2 , Lammers V 2 , Aubert RE 1 1 Medco Health Solutions, Franklin Lakes, NJ, USA; 2 Europa Apotheek Venlo B.V., Venlo, The Netherlands OBJECTIVES: Quasi-experimental analysis to determine the effect of an opt-in telephone intervention on adherence in patients using subcutaneous interferon β-1a, which is indicated for relapsing-remitting multiple sclerosis. Drop-out reasons, sideeffects, and expectations of therapy are described. METHODS: Customers of a mailorder pharmacy that services Germany who ordered subcutaneous interferon β-1a were targeted for enrollment in a free program that included an initial counseling call, optional e-mail reminders for the next doctor's consultation and prescription, and ongoing counseling calls. Patients enrolled in the program for at least 6-months were included in the analysis and compared to patients that did not enter the program over the same time period. Proportion of days covered (PDC) was calculated for each group and compared using analysis of variance. Enrollees in the program were administered a questionnaire at the initial welcome call addressing their expectations of therapy, and again during each counseling call regarding their compliance behavior, and side effects. RESULTS: Patients in the adherence program showed an unadjusted PDC 8.2% higher than the control, F(1.247) = 13.44, p = 0.0003. One program patient switched drugs compared to six control group patients. a total of 21% of enrolled subjects reported missing at least one dose. Side-effects included pain/infl ammation at the site of injection (24.41%), fatigue (20.73%), headaches (17.06%), and fl u-like symptoms (9.71%). Exacerbations were reported by 15.7% of patients. Patients' had expectations that therapy would prolong the distance between exacerbations (23.36%) and slow the progression of disability due to the disease (21.28%). CONCLUSIONS: Actively recruiting patients into an optional adherence program signifi cantly increased the compliance rate for relapsing-remitting multiple sclerosis patients using subcutaneous interferon β-1a. Side effects experienced by enrolled patients were consistent with the package insert. Limitations include a potential bias between patients that agree to the program vs. those that do not, as well as the lack of additional questionnaire data from the control group.
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INFLUENCE OF AGE ON REFILL-ADHERENCE RATES OF ANTI-EPILEPTIC DRUGS IN SOUTH AFRICA
Van Zyl T, Lubbe MS, Serfontein JHP, Rakumakoe DM North-West University, Potchefstroom, South Africa OBJECTIVES: To investigate the possible infl uence of age on the refi ll-based adherence rates of anti-epileptic drugs. METHODS: A retrospective drug utilization review was performed on medicine claims data of a pharmacy benefi t management company in South Africa. Refi ll-based adherence rates were calculated for 64,457 anti-epileptic drugs that were prescribed more than once during a four-year period (January 1, 2005 to December 2008). The refi ll-based adherence rate was calculated per trade name by using the following equation: Refi ll-Adherence rate = (total number of days of antiepileptic drugs supplied-days supplied at the last refi ll)/(date last claimed-date fi rst claimed). [RSA Rand (R)/$US = 6.38112 (2005); 6. 78812 (2006); 7.06926 (2007) and 8.27505 (2008) ]. RESULTS: Only 30.5% (n = 19 635) of anti-epileptic drugs had refi ll-adherence rates between between 90% and 110%. The majority of anti-epileptic drugs (58.9%; n = 37 962) had refi ll-adherence rates below 90% that accounted for 39.2% (n = R 57 599 838) of the total cost of all anti-epileptic drugs (N = R146 863 755) included in these calculations. Anti-epileptic drugs with refi ll-adherence rates >110% (10,7%; n = 6 860) accounted for 6.7% (R9 782 864) of the total cost of all anti-epileptic drugs. The average refi ll-adherence rate decreased with nearly 10% from
